• Corpus ID: 23517930

L-carnitine addition to dialysis fluid. A therapeutic alternative for hemodialysis patients.

@article{Vacha1989LcarnitineAT,
  title={L-carnitine addition to dialysis fluid. A therapeutic alternative for hemodialysis patients.},
  author={Gian Maria Vacha and Giovanni Giorcelli and Stefania D'Iddio and Giovanni Valentini and Emilia Bagiella and Alberto Procopio and Stefano di Donato and Donald Ashbrook and Marco Corsi},
  journal={Nephron},
  year={1989},
  volume={51 2},
  pages={
          237-42
        }
}
L-Carnitine has been reported to have beneficial effects in the reduction of serum triglycerides and increases high-density lipoprotein cholesterol in hemodialysis patients. The published reports are, however, equivocal. Paradoxical increases in serum triglycerides following intravenous administration of L-carnitine have been observed. It has been suggested that the paradoxical rise in triglycerides may result from the high doses used and intravenous administration, both of which may cause… 

Significance of Levocarnitine Treatment in Dialysis Patients

Previous research into levocarnitine therapy in patients on maintenance dialysis for the treatment of renal anemia, cardiac dysfunction, dyslipidemia, and muscle and dialytic symptoms is reviewed, and the efficacy of the therapeutic approach and related issues are examined.

L‐Carnitine Administration to Hemodialysis Patients: Has Its Time Come?

The data regarding the efficacy of L-carnitine supplementation in the correction of these disorders in chronic hemodialysis (HD) patients is reviewed to suggest appropriate therapeutic regimens.

L‐carnitine supplementation in the dialysis population: Are Australian patients missing out? (Review Article)

SUMMARY:  It has been widely established that patients with end‐stage renal disease undergoing chronic haemodialysis therapy exhibit low endogenous levels of L‐carnitine and elevated acylcarnitine

Carnitine: An Overview

Carnitine, a small dialyzable molecule of molecular weight 162 daltons, has been used to treat the cardiovascular and neuromuscular symptoms of dialysis patients. To most nephrologists, however, the

Pharmacokinetics and Safety of Intravenous Ferric Pyrophosphate Citrate: Equivalence to Administration via Dialysate

Bioequivalence parameters showed that infusion of FPC iron IV, predialyzer and postdialyzer delivered equivalent iron as via hemodialysate, the same as observed in the long‐term clinical studies of F PC.

Optimizing haemodialysate composition

An adequate dialysate glucose concentration prevents severe hyperglycaemia and life-threating hypoglycaemia, which can lead to severe cardiovascular complications and a worsening of diabetic comorbidities.